Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04882579
Other study ID # PulmonaryEmbolismPoCUSOdense
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date June 15, 2021
Est. completion date July 1, 2023

Study information

Verified date November 2023
Source Odense University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pulmonary embolism (PE) is a common cardiovascular condition with an estimated incidence of 0.60 to 1.12 per 1000 inhabitants in the United States of America, and the diagnosis is challenging as patients with PE present with a wide array of symptoms. Computed tomography pulmonary angriography (CTPA) and lung ventilation-perfusion scintigraphy (VQ) are considered the gold-standards in PE-diagnostics but may not always be feasible. CTPA is contraindicated by contrast allergy or renal failure and both modalities require involvement of multiple staff-members and transport of the patient. Lung scintigraphy cannot be performed in an emergency situation, with unstable patients and patients unable to comply to the examination. Ultrasound represent a possible tool in confirming or dismissing clinical PE suspicion. Ultrasound is non-invasive and can be performed bedside by the clinician, an approach known as point-of-care ultrasound (PoCUS), reducing both time, radiation-exposure and costs. The aim of this study is to investigate whether integrating cardiac, lung and deep venous ultrasound in the clinical evaluation of suspected PE reduces the need for referral to CTPA or lung scintigraphy, during emergency department work up, while maintaining safety standards.


Description:

All ultrasound examinations will be performed by a physician certified in ultrasound by the Danish Society for Emergency Physicians in accordance with the Danish Health Agency. Based on ultrasonographic findings, PE suspicion is allocated to one of three categories: 1. Clinical suspicion of PE confirmed if ≥1 of the following ultrasound findings: 1. Visible proximal deep venous thrombus 2. ≥2 hypoechoic subpleural lung consolidations with a diameter of ≥0,5cm 3. Visible right ventricular thrombus 4. McConnell's sign if no known pulmonary hypertension, interstitial lung disease, COPD or pulmonary valve disease 5. D-sign present in both systole and diastole if no known pulmonary hypertension, interstitial lung disease, COPD or pulmonary valve disease If PE is confirmed by ultrasound, the physician will apply the simplified pulmonary embolism severity index score (sPESI) and estimate risk of mortality within 30 days based on clinical signs and symptoms, cardiac troponin level and RV dysfunction. Patients with intermediate-high or high risk, requiring admission to a cardiology department will be referred for CTPA. Patients with low or intermediate-low risk, not requiring admission, will be discharged with anticoagulative treatment. A thorough presentation of the sPESI-score and early mortality risk assessment is available in the 2019 collaborative guidelines by the ERS and ESC on the diagnosis and management of PE. 2. Further diagnostic imaging (CTPA or V/Q) required if ≥1 of the following ultrasound findings: 1. 1 hypoechoic subpleural lung consolidation with a diameter of ≥0,5cm 2. Pleural effusion not explained by other cause 3. Basal RVEDD/LVEDD >1.0 or an RV visibly larger than the LV 4. TAPSE <17 mm 5. No deep venous thrombus, no lung consolidation or effusion, no signs of RV strain or thrombus but strong clinical suspicion. 6. McConnell's or D-sign in the presence of known pulmonary hypertension, interstitial lung disease, COPD or pulmonary valve disease If PE suspicion can be neither dismissed nor confirmed after ultrasound investigation, the patient will be referred to further investigation as usual with CTPA or lung scintigraphy. Subsequent plan will be in accordance with department guidelines. 3. Clinical suspicion of PE dismissed if ≥1 of the following ultrasound findings: 1. No deep venous thrombus, no lung consolidation or effusion, no signs of RV strain or thrombus and a plausible differential diagnosis or low clinical suspicion 2. Obvious differential diagnosis demonstrated on ultrasound (i.e., pneumonia, pneumothorax, interstitial syndrome, left sided heart failure) If PE suspicion is dismissed by ultrasound investigation, the patient will be either discharged or subject to further investigations in accordance with department guidelines if indicated.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date July 1, 2023
Est. primary completion date February 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Referred or Admitted to an emergency department - Clinical suspicion of PE raised by physician requiring further diagnostic imaging (Well's score 0-6 with elevated age-adjusted D-dimer or Wells score >6 regardless of D-dimer) Exclusion Criteria: - Refusal of informed consent - Pregnancy - Permanent mental disability - Age <18 years - Diagnosis of PE within the last 6 months - Hemodynamic instability (systolic blood pressure <90 mmHg for at least two consecutive measurements) - Ultrasound of heart, lungs or deep veins performed prior to enrollment

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Point-of-care-ultrasound examination
The intervention consists of three ultrasound modalities: Cardiac ultrasound assessing signs of right ventricular strain or other obvious pathology. Deep venous ultrasound assessing presence of a deep venous thrombus Lung ultrasound assessing presence of pulmonary infarctions, pleural effusion, pneumothorax or interstitial syndrome.

Locations

Country Name City State
Denmark Esbjerg Hospital Esbjerg
Denmark Kolding Hospital Kolding
Denmark Odense University Hospital Odense
Denmark Slagelse hospital Slagelse
Denmark Svendborg Hospital Svendborg

Sponsors (4)

Lead Sponsor Collaborator
Odense University Hospital Odense Patient Data Explorative Network, Snedkermester Sophus Jacobsen and hustru Astrid Jacobsens Foundation, University of Southern Denmark

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients referred to CTPA or VQ after multiorgan PoCUS Up to 24 hours
Secondary Number of adverse events in the intervention and control group after inclusion, including readmission, serious bleeding or death 3 months
Secondary Number of hours until initiation of relevant treatment after clinical evaluation in the control and intervention group. Up to 24 hours
Secondary Proportion of included patients diagnosed with PE in the control and intervention group Up to 24 hours
Secondary Proportion of patients diagnosed with alternative diagnosis following clinical evaluation in the intervention and control group Up to 24 hours
Secondary Proportion of patients in the intervention and control group discharged to their own home following clinical evaluation Up to 24 hours
Secondary Proportion of patients in the reference and control group admitted to a cardiology department for telemetry monitoring (i.e. high risk PE) following clinical evaluation. Up to 24 hours
Secondary Proportion of patients in the reference and control group admitted to an intensive care unit following clinical evaluation Up to 24 hours
Secondary Proportion of patients in the reference and control group referred to supplementary CTPA or lung scintigraphy within 30 days after inclusion 30 days
Secondary Total costs related to diagnostic work up and hospital stay as assessed by HEAT 4.2 Up to 1 year
Secondary Number of subsequent cancer diagnosis in the intervention and control group within 3 months of inclusion 3 months
See also
  Status Clinical Trial Phase
Recruiting NCT05050617 - Point-of-Care Ultrasound in Predicting Adverse Outcomes in Emergency Department Patients With Acute Pulmonary Embolism
Terminated NCT04558125 - Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism Phase 4
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Completed NCT03915925 - Short-term Clinical Deterioration After Acute Pulmonary Embolism
Completed NCT02502396 - Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
Recruiting NCT05171075 - A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE Phase 3
Completed NCT04454554 - Prevalence of Pulmonary Embolism in Patients With Dyspnea on Exertion (PEDIS)
Completed NCT03173066 - Ferumoxytol as a Contrast Agent for Pulmonary Magnetic Resonance Angiography Phase 1
Terminated NCT03002467 - Impact Analysis of Prognostic Stratification for Pulmonary Embolism N/A
Completed NCT02611115 - Optimizing Protocols for the Individual Patient in CT Pulmonary Angiography. N/A
Completed NCT02334007 - Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery Phase 1/Phase 2
Completed NCT01975090 - The SENTRY Clinical Study N/A
Not yet recruiting NCT01357941 - Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE) N/A
Completed NCT01326507 - Prognostic Value of Heart-type Fatty Acid-Binding Protein (h-FABP) in Acute Pulmonary Embolism N/A
Completed NCT02476526 - Safety of Low Dose IV Contrast CT Scanning in Chronic Kidney Disease Phase 4
Completed NCT00780767 - Angiojet Rheolytic Thrombectomy in Case of Massive Pulmonary Embolism Phase 2
Completed NCT00771303 - Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
Completed NCT00773448 - Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism N/A
Completed NCT00720915 - D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months N/A
Completed NCT00816920 - Natural History of Isolated Deep Vein Thrombosis of the Calf